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AbstrACt 
Objective To conduct a systematic review investigating 
the normal age-related changes in lung function in adults 
without known lung disease. 
Design Systematic review. 
Data sources  MEDLINE, Embase and Cumulative Index 
to Nursing and Allied Health Literature (CINAHL) were 
searched for eligible studies from inception to February 12, 
2019, supplemented by manual searches of reference lists 
and clinical trial registries. 
Eligibility criteria We planned to include prospective 
cohort studies and randomised controlled trials (control 
arms) that measured changes in lung function over time in 
asymptomatic adults without known respiratory disease.
Data extraction and synthesis Two authors 
independently determined the eligibility of studies, 
extracted data and assessed the risk of bias of included 
studies using the modified Newcastle–Ottawa Scale.
results From 4385 records screened, we identified 
16 cohort studies with 31 099 participants. All included 
studies demonstrated decline in lung function—forced 
expiratory volume in 1 s (FEV
1), forced vital capacity (FVC) 
and peak expiratory flow rate (PEFR) with age. In studies 
with longer follow-up (>10 years), rates of FEV1 decline 
ranged from 17.7 to 46.4 mL/year (median 22.4 mL/year). 
Overall, men had faster absolute rates of decline (median 
43.5 mL/year) compared with women (median 30.5 mL/
year). Differences in relative FEV
1 change, however, were 
not observed between men and women. FEV1/FVC change 
was reported in only one study, declining by 0.29% per 
year. An age-specific analysis suggested the rate of FEV1 
function decline may accelerate with each decade of age.
Conclusions Lung function—FEV1, FVC and PEFR—
decline with age in individuals without known lung 
disease. The definition of chronic airway disease may 
need to be reconsidered to allow for normal ageing and 
ensure that people likely to benefit from interventions are 
identified rather than healthy people who may be harmed 
by potential overdiagnosis and overtreatment. The first 
step would be to apply age, sex and ethnicity-adjusted 
FEV
1/FVC thresholds to the disease definition of chronic 
obstructive pulmonary disease.
PrOsPErO registration number CRD42018087066.
IntrODuCtIOn
In 2016, the WHO estimated that chronic 
obstructive pulmonary disease (COPD) 
affected 251 million people worldwide, 
with its prevalence continuing to rise with 
an ageing population.1 Current guidelines 
in UK,2 Australasia,3 Europe and the USA4 
recommend that COPD is diagnosed if an 
individual has symptoms such as dyspnoea 
or sputum production, if they have known 
risk factors such as smoking or biomass fuel 
exposure and if they demonstrate post-bron-
chodilator airflow limitation on spirometry. 
Airflow limitation on spirometry is defined 
when the ratio of forced expiratory volume 
in 1 s (FEV1) to forced vital capacity (FVC) 
is less than 70% after bronchodilator admin-
istration.2 3 However, this arbitrary diagnostic 
threshold has attracted criticism as it does not 
adjust for age or sex.5–10
Ageing is invariably accompanied by 
changes in lung function due to factors such 
as loss of lung elasticity, weakened muscles 
of respiration, and decreased surface area 
for alveolar gas exchange. Several published 
cross-sectional studies9 11–13 and longitudinal 
studies14 15 report that lung function param-
eters such as FEV1 and FVC decline with age.
The 2018 update of the Global Initiative for 
Chronic Obstructive Lung Disease (GOLD) 
strengths and limitations of this study
 ► This is the first review to provide estimates for the 
median decline in spirometry measures including 
the forced expiratory volume in 1 s (FEV1), forced 
vital capacity (FVC) and the FEV1/FVC ratio based on 
longitudinal data.
 ► We used a modified version of the Newcastle–
Ottawa Scale to assess risk of bias.
 ► The review may be prone to volunteer bias, and 
therefore may underestimate lung function decline 
among asymptomatic people.
 ► Only one study specifically reported the change of 
the FEV1/FVC ratio with age, and we did not have 
access to unpublished individual participant data 
to allow calculation of the FEV1/FVC ratio change 
where this was not reported. 
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criteria16 continues to suggest the use of the fixed ratio 
rather than an FEV1 or FVC that lies outside of the lower 
limit of normal (LLN) range. While the fixed ratio 
threshold may be simple for clinicians to use, it does not 
consider that lung function measurements may change 
with age and vary with gender and ethnicity. Many labora-
tory tests already have different reference range values for 
different ages and electronic spirometry machines do the 
same. The GOLD criteria acknowledge that this arbitrary 
fixed threshold may overdiagnose normal healthy older 
adults as diseased and underdiagnose some younger 
people with disease as healthy.17 18
Longitudinal studies need to be identified so that 
normal changes in lung function can be calculated for 
different ages. Monitoring change could be used in 
practice to complement a single time point measure-
ment to identify people who are not within the expected 
normal range. We aimed to perform a systematic review 
of prospective cohort studies and randomised controlled 
trials that examined changes in lung function with age 
in asymptomatic individuals with no known lung disease 
who have never smoked. This knowledge would enable 
further work to develop age-specific, sex-specific and 
ethnicity-specific estimates that may be especially useful 
in a primary care setting. This implies that people are 
only diagnosed with COPD if their spirometry measure-
ments fall outside of the normal range for their age, sex 
and ethnicity, rather than on the basis of a fixed value.
MEthODs
Protocol registration
The protocol for this review was drafted in accordance with 
the Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses (PRISMA) statement and the Meta-anal-
yses of Observational Studies in Epidemiology (MOOSE) 
reporting guidelines. It was registered on PROSPERO 
and is available from http://www. crd. york. ac. uk/ PROS-
PERO/ display_ record. php? ID= CRD42018087066, see 
online supplementary file 1.
search strategy and inclusion criteria
We conducted electronic searches of MEDLINE, EMBASE 
and Cumulative Index to Nursing and Allied Health 
Literature  (CINAHL) databases from inception through 
to February 2019, using the search strategy specified in 
online supplementary file 2. This was developed with an 
information specialist. Electronic searches were comple-
mented by manual searching through reference lists of 
studies that were identified for potential inclusion as well 
as backward and forward searching. We also searched the 
WHO Clinical Trials registry and  ClinicalTrials. gov regis-
tries using the key words “normal ageing”, “lung func-
tion decline”, “FEV1 decline”, “FVC decline” and “lung 
decline”.
We included cohort studies and also planned to include 
the control arms of randomised controlled trials that 
measured the decline of lung function in an ageing popu-
lation. The inclusion criteria were:
 ► Longitudinal studies that followed some or all of the 
adult participants past the age of 65 years.
 ► Three or more measurements of lung function 
undertaken.
 ► Studies with a follow-up period of 3 years or longer.
 ► Studies that measure lung function (ie, FEV1, FVC, 
peak expiratory flow rate (PEFR)).
We excluded studies if the participants did not meet the 
prespecified age criteria; if the population of interest were 
reported to include smokers or those with risk factors such 
as occupational inhalation; if participants were reported 
to have respiratory symptoms such as wheeze, dyspnoea 
or chronic cough or if the study included participants 
with known respiratory disease such as asthma or COPD.
study selection and data extraction
Two authors (ETT, MG) independently screened the titles 
and abstracts of studies identified in the initial search 
for eligibility. Prior to commencing screening, a small 
subset of 50 titles were screened by the two reviewers 
as a calibration exercise to check for >80% agreement. 
Similarly, after screening, a calibration exercise was 
conducted for screening the full texts of the studies and 
targeting >80% agreement. The remaining full texts were 
retrieved and reviewed independently by the authors to 
determine eligibility for inclusion. Non-English publica-
tions were translated using Google Translate or with the 
assistance of a translator. Disagreements were resolved 
by consensus through discussion or with a third reviewer 
(PG). If there were multiple reports of the same study, the 
most recent publication with longest length of follow-up 
was selected for inclusion, and if the two studies had a 
similar length of follow-up then the study with the largest 
sample size was included. Two authors independently 
extracted data from the studies. The Excel data extraction 
form was piloted using 10 studies prior to data extraction 
as a calibration exercise to check for adequate agreement 
(>80%) between the reviewers. Any disagreements were 
resolved by consensus or with a third reviewer. Extracted 
measures included study setting, year and duration, 
participant eligibility criteria, sample size, participants 
demographics (ethnicity, gender, baseline age), any 
known risk factors or exposures, baseline lung function, 
lung function measurements, number and frequency of 
measurements, average length of follow-up and loss to 
follow-up. We also aimed to report the proportion of the 
cohort that subsequently developed symptoms or disease 
during follow-up.
We assessed risk of bias of included studies using the six 
items of the Newcastle–Ottawa Scale (NOS)19 for assessing 
quality of included cohort studies. Disagreements were 
resolved by discussion or a third reviewer.
Assessed factors included:
 ► Representativeness of the exposed cohort (eg, low 
risk: random selection; high risk: non-random selec-
tion for example, volunteer sampling).
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 ► Ascertainment of exposure—age (eg, low risk: from 
medical records; high risk: self-reported).
 ► Demonstration that the outcome of interest was not 
present at the start of study (eg, low risk: partici-
pants were excluded on the basis of demonstrated 
airflow limitation; high risk: if participants were not 
screened).
 ► Assessment of outcome (eg, low risk: spirometry; high 
risk: subjective measure of lung function).
 ► Adequate duration of follow-up (eg, low risk: ≥3 years 
of follow-up; high risk: <3 years of follow-up).
 ► Adequate follow-up of cohorts (eg, low risk: <20% 
attrition, loss to follow-up explained; high risk: >20% 
attrition, unexplained loss to follow-up).
Studies were assessed as good quality if they had low risk 
of bias in all six domains, moderate quality if they had low 
risk of bias in four or five domains and low quality if they 
had low risk of bias for three or fewer domains.
statistical analysis
For each study cohort, we extracted the annual decline 
rates for each lung function measure. If these were not 
reported, we calculated crude decline rates for all reported 
lung function measure by subtracting the final measure 
from the initial measure and dividing the result by the 
duration of follow-up. If these data were not available, 
we determined crude rates of decline from the graphs 
provided or contacted the study authors for original data. 
The data were first analysed descriptively using graphs to 
determine whether it was appropriate to pool the data. 
For continuous outcomes, the mean difference (MD) 
(or standardised MD if studies used different measuring 
scales) and SD were calculated. The data were reported 
as an annual decline (unit/year). The overall rates of 
decline and corresponding 95% CIs were presented in 
a forest plot. We planned to perform a meta-analysis to 
pool the estimates of decline.
We presented the data by functional parameter (FEV1, 
FEV0.75, FVC, PEFR) and planned to compare annual 
decline rates by sex and ethnicity in absolute and rela-
tive terms, where data were available. We also extracted 
and presented age-specific decline rates by decade of age 
if studies reported these data. We planned to separately 
analyse the data of those who developed disease during 
follow-up. We also planned to examine for birth cohort 
effects if the data were available. Sensitivity analyses were 
planned for study duration greater than 10 years.
Patient and public involvement
Patients were not involved in the design, data extraction 
or data analysis of this review.
rEsults
study characteristics
From searches of MEDLINE, Embase and CINAHL 
performed on 12 February 2019, we identified 4331 
records. An additional 54 records were identified from 
clinical trial registries and reference list searches. From 
these, we retrieved 143 papers for full text review; 115 of 
these did not meet our selection criteria and a further 12 
were removed as duplicates. In total, 16 studies20–35 were 
included in the systematic review (with one study contrib-
uting two data sets29) (figure 1). The studies included 
31 099 participants and were conducted between 1959 
and 2014 ranging from 5 to 30 years in duration (table 1).
Overall age-related lung function decline
A meta-analysis was not performed due to substantial 
heterogeneity across the included studies, and a narra-
tive synthesis was undertaken instead. Thirteen studies 
reported changes in FEV1 as an outcome. All studies 
demonstrated a decline with age, with overall rates of 
decline from each study ranging from 9.9 to 56.0 mL/
year (median 29.2 mL/year). Seven of these studies exam-
ined the differences in rates of decline between males 
and females, showing greater absolute FEV1 decline in 
males (median 43.5 mL/year) than in females (median 
30.5 mL/year) (table 2, figure 2). Relative rates of FEV1 
decline were calculated for men in eight studies and 
for women in six studies that reported baseline FEV1 
values. There was no statistically significant difference 
between men and women’s relative change of FEV1 from 
baseline (p=0.7). FEV0.75 decline was reported in one 
study.29 This study provided two data sets (follow-up after 
15 years, 30 years) provided in table 2.
Five studies reported changes in FVC, with rate of 
decline estimates ranging from 14.1 mL/year in the 
Figure 1 Study flow diagram showing the process for 
inclusion of prospective randomised controlled trials (RCTs) 
and cohort studies for estimating the rate of lung function 
decline with age.
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youngest cohort32 (median age 36.2 years) to 65.6 mL/
year in the older cohort24 (mean age 73.0 years). In studies 
that measured both FEV1 and FVC over time, there was 
a greater decline in FEV1 than FVC in two studies, and 
greater decline in FVC than FEV1 in three studies. These 
measures are average estimates across study participants 
and do not enable calculation of individuals’ FEV1/
FVC ratios. In the one study where individuals’ FEV1/FVC 
ratios were reported as an outcome,26 there was a decline 
by 0.29% per year.
PEFR was reported as an outcome in two studies,27 30 
which showed decline rates ranging from −6.6 L/min/
year in females to −11.5 L/min/year in males.
Age-specific lung function decline by decade of age
The age-specific rates of FEV1 change by decade of age 
were extracted or calculated from three studies.22 23 28 35 In 
all but one study, estimates of decline increased from the 
fourth (age 30–40 years) to eighth decades of life (table 3). 
One study could not be included in this comparative 
analysis as they included smokers and reported decline 
rates at the end of study follow-up (rather than base-
line age).35 This study reported that the rates of relative 
decline increase from the seventh (−1.7 %/year) through 
to the tenth decade (−3.1 %/year), though absolute rates 
of decline varied. Another study also reported that the 
rate of decline may be non-linear in multiple regression 
models of FEV1 and FVC decline (where age squared was 
also a statistically significant variable).34
Two studies examined lung function change within 
age brackets that did not conform to our decade-specific 
analysis. Bartholomew and Knuiman21 reported greater 
decline rates in never smokers aged above 45 years 
(females: −30.7 mL/year, males −45.8 mL/year) compared 
with those aged below 45 years (females: −24.3 mL/year, 
males: −36.8 mL/year). Lange et al25 compared decline 
rates in both male and female non-smokers in 20-year 
age groups. Females aged 60–79 years had the greatest 
decline rates (−31.7±2.1 mL/year) compared with the 
40–59 age group (−17.7±1.4 mL/year) and the 20–39 age 
group which reported an increase of 5.0±2.7 mL/year. 
Similarly, males aged 60–79 years had the greatest decline 
rates (−37.1±3.7 mL/year) compared with the 40–59 year 
age group (−24.2±2.6 mL/year) and the 20–39 year age 
group (−4.6±4.2 mL/year).
Overall rates of mortality/symptom/disease development
Few studies reported these outcomes in an initially 
asymptomatic, non-smoking population. One study 
(Proctor et al)30 reported 85% mortality rate in the elderly 
cohort (age range 79–96) over 8 years. Another study 
(Lange et al)25 reported that in their study of non-asth-
matics, 364 (2%) patients who did not report having 
asthma at the beginning of the study, later reported it in 
follow-up. However, this estimate included smokers. One 
study (Wang and Petsonk)33 performed their analyses on 
a highly screened population, meaning they excluded 
participants from all analyses who developed disease or S
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symptoms during study follow-up. No studies reported 
the rates of lung function change in those who developed 
disease during the course of the study compared with 
those who did not.
sensitivity analyses
Heterogeneity in study duration was explored in figure 3. 
After removing studies with a follow-up of less than 10 
years, the median rate of decline of FEV1 was 22.4 mL/
year (figure 4).
Predictors of the rate of decline in lung function in people 
without known lung disease
Smoking
Although smokers were not included in our main anal-
ysis, some studies did compare non-smokers and smokers 
which we report here. The decline rates were compared 
in non-smokers or former smokers with current smokers 
in nine studies.21 22 24–27 29 31 35 In the seven studies 
measuring FEV1 decline, current smokers were observed 
to have a faster rate of decline.21 22 24–26 31 35 In the 
three studies measuring FVC, smoking increased FVC 
decline.21 24 35 FEV1/FVC decline was greater in smokers 
than non-smokers in one study26 and FEV0.75 in another 
study.29
Body mass index (BMI)
Three studies reported the association of BMI with FEV1 
change. In the study by Bartholomew and Knuiman,21 
increased BMI significantly affected FEV1 decline 
(p=0.008 for females; p=0.007 for males). However, an 
estimate for this association was not provided. In Triebner 
et al,32 obese individuals reported greater declines of 
FEV1 (29 mL/year) and FVC (25 mL/year) compared 
with individuals with normal BMI (FEV122 mL/year, FVC 
10 mL/year). In Luoto et al,35 having a BMI greater than 
35 was significantly associated with a slower decline of 
FEV1 (32 mL/year compared with 46 mL/year, p=0.04), 
but it did not significantly affect FVC decline.
Ethnicity
Griffith et al24 was the only study that assessed ethnicity, 
specifically comparing African-American participants to 
white participants. We did not include the African-Amer-
ican cohort in our analysis as only two measurements 
were performed on this population. However, FEV1 and 
FVC declines were greater in whites compared with 
African-Americans.
Systolic blood pressure
Griffith et al24 examined the correlation of systolic blood 
pressure greater than 160 mm Hg with FEV1 and FVC 
decline and found that declines were on average 5.6 mL/
year and 10.9 mL/year greater, respectively (p<0.01).
Dust exposure
Liao et al26 explored the effects of dust exposure on FEV1 
and FEV1/FVC decline. Participants with more dust expo-
sure experienced a mean FEV1 decline that was 4.5 mL/
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year greater than participants with less dust exposure 
(p=0.007). Dust exposure did not significantly affect 
FEV1/FVC ratio decline, suggesting that FVC declined in 
parallel to FEV1.
Menopausal status
Triebner et al32 reported that menopausal status affected 
the rate of decline, with rates of FEV1 decline on average 
3.8 mL/year greater in perimenopausal women, and 
5.2 mL/year greater in postmenopausal women. FVC 
decline was 10.2 mL/year greater in perimenopausal 
women and 12.5 mL/year greater in postmenopausal 
women, compared with premenopausal women.
risk of bias
Risk of bias was determined using a modified version of 
the NOS19 (figures 5 and 6). No studies received low risk 
of bias in all domains, but four studies had a low risk of bias 
in all but one domain.23 28 31 Thirteen studies (81%) were 
graded as having low risk of bias for representativeness 
of the population. Six studies (38%) were judged as low 
risk of bias on how they ascertained the age of the partic-
ipants (from Medicare eligibility lists or health records). 
Four cohort studies (25%) clearly demonstrated that 
pulmonary impairment was not present in participants 
at the beginning of the study. All studies (100%) used a 
Figure 2 The rate of forced expiratory volume in 1 s (FEV1) decline in 13 study populations, grouped by sex.
Table 3 Age-specific lung function decline by decade of age as reported in four cohorts
Absolute mean decade-specific FEV1 function decline rates (mL/year)
Study ID Sample size (n)
Baseline age (years)
30–39 40–49 50–59 60–69 70–79
Burchfiel, 199522* Male
(1248)
−19.5† −21.6 −25.0
Burrows, 198623 Male
(158)
2.83 −3.01 −8.85 −14.69 −20.53
Female
(308)
2.73 −2.51 −7.76 −13.01 −18.26
Pearson, 199828 Female
(82)
−23.8 −33.4 −30 −23.4 −25.8
Male
(91)
−34 −34 −34 −34 −34
The estimates from Burrows were derived from formulae modelling change in FEV1 with age. See online supplementary file 3 for calculations. 
*Estimates adjust for covariates including height and age.
†Includes participants aged 45–49 years.
FEV1, forced expiratory volume in 1 s.
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spirometer to measure lung function which is a validated 
objective instrument. All studies (100%) had adequate 
duration of follow-up (3 years or longer). Eight studies 
(50%) had a high risk of bias for having high attrition 
rates in their studies (>20%).
DIsCussIOn
statement of principal findings
This systematic review of 16 prospective cohort studies 
conducted in 13 countries provides a summary of all the 
available evidence looking at lung function change with 
age. Lung function declines with age in normal, asymp-
tomatic adults with higher rates of decline in absolute 
lung function parameters in men compared with women. 
However, the relative rates of decline from baseline between 
men and women do not differ significantly. The decline in 
absolute and relative lung function parameters may accel-
erate with age and is also exacerbated by smoking. We were 
unable to compare lung function decline rates of different 
ethnicities due to insufficient data. There was a paucity of 
longitudinal studies that reported changes in FEV1/FVC 
rather than reporting the two parameters separately.
Figure 3 The rate of forced expiratory volume in 1 s (FEV1) decline in 13 study populations by years of follow-up. The size of 
the circle corresponds to individual study sample size.
Figure 4 Sensitivity analysis, excluding studies with less than 10 years of follow-up. The size of the circle corresponds to 
individual study sample size. FEV1, forced expiratory volume in 1 s. 
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strengths and weaknesses of the study
This systematic review examined all the available primary 
studies to allow an examination of the consistency of esti-
mates of decline in FEV1, FVC, FEV1/FVC ratio and PEFR. 
This review particularly focused on older adults; this 
group is relatively understudied and yet more prone to 
overdiagnosis and misdiagnosis.6 8 18 While the majority of 
current prediction equations of lung function are based 
on cross-sectional studies,36–39 our review searched for 
longitudinal studies as they change in lung function may 
provide a complement to measurement at one time point 
in predicting future lung function.37 Our review included 
participants who were ageing normally, but may have had 
non-pulmonary comorbidities such as hypertension and 
diabetes mellitus. This enabled us to investigate a popu-
lation that was more representative of a normal ageing 
population.
Our review has some limitations. We did not have 
access to unpublished individual participant data to 
allow the calculation of FEV1/FVC for the majority of 
studies, where this were not reported. Five studies sepa-
rately measured changes in both FEV1 and FVC, however 
is difficult to conclude whether the rate of decline in 
FEV1 and FVC is proportional. Out of the five studies 
that reported both FEV1 and FVC decline, two studies
32 
demonstrated that FEV1 declines faster than FVC, but in 
the three remaining studies,20 21 24 the FVC declined at a 
faster rate (see table 2). Longitudinal studies that specif-
ically measure the FEV1/FVC would provide the most 
reliable measure of this decline. Individual patient data 
would also allow a more robust analysis of changes in lung 
function between individuals in the studies.
We were unable to pool the results due to significant 
heterogeneity across the populations. This review’s find-
ings are also limited by the quality of the included studies, 
all of which were judged moderate or low quality. Since 
this review is based on limited populations, the findings 
may not be generalisable to all individuals, especially 
those of non-Caucasian ethnicities or from less econom-
ically developed countries where smoking and air pollu-
tion may be more prevalent for example. The review’s 
findings may underestimate lung function decline among 
asymptomatic people, as volunteer bias may be present 
with cohort studies where healthier individuals may be 
more likely to participate. Our study aimed to examine 
the rate of lung function change in the elderly group; 
however, the majority of included studies did not focus 
on this age group. COPD misdiagnosis particularly affects 
those older than 80 years of age; therefore, more studies 
are required in the elderly group.
Our review did not consider the extent of short-term 
within-person variation, or ‘noise’, in lung function 
measurements, which is likely to be considerable.40 41 
Any observed change in measurement is a combination 
of the true change, or ‘signal’, and the random back-
ground ‘noise’. The clinical utility of monitoring lung 
function to decide whether or not COPD is present 
is in part determined by the ratio of signal to noise in 
Figure 5 Risk of bias summary for prospective cohort 
studies estimating the rate of lung function decline with age, 
assessed using a modified form of the Newcastle–Ottawa 
Scale. 
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the measurements.42 Changes in measured lung func-
tion over a longer period of time may be more likely to 
indicate some true change rather than just background 
noise43; therefore, we specified in our inclusion criteria 
that eligible studies should measure lung function on a 
minimum of three occasions.
We observed substantial heterogeneity across all the 
included studies and results. This may be due to inherent 
differences within the populations studied (including 
distribution of ages, proportion of men vs women and 
ethnicities) or the duration of follow-up, or that decline 
in normal healthy people may vary across individuals 
without causing disease. We explored differences in dura-
tion of follow-up as a potential source of heterogeneity 
in a sensitivity analysis excluding studies with less than 10 
years of follow-up, but found that this did not change the 
median estimate substantially.
Quality of spirometry, as well as properly maintained 
and calibrated equipment, causing measurement error 
and contributing to the ‘noise’ in measurement discussed 
above, is likely to have contributed to variation in the 
results. Only nine of the included studies specifically 
reported that the spirometers used in their studies were 
calibrated and the measurements had to be acceptable 
and reproducible, following the American Thoracic 
Society guidelines on the standardisation of spirometry.44 
Two studies used peak flow meters to measure PEFR. 
These instruments are well known to vary in consistency 
and accuracy. Maselko et al used a Mini-Wright meter, but 
the second study by Proctor et al did not specify which 
peak flow meter they used.
The majority of studies specified that they excluded 
patients with known disease or symptoms at the 
commencement of the study. However, most of the studies 
did not report whether any of the participants in their 
study sample developed symptoms or respiratory disease 
in the course of follow-up. Thus, undiagnosed COPD or 
other respiratory, cardiac, renal or other diseases that 
cause decline in lung function may have contributed to 
heterogeneity in the results.
Variation within the results may be also explained 
by the ‘horse-racing effect’, where an initially low FEV1 
measurement may reflect a greater loss of function in 
the preceding years and hence predicts faster decline 
in subsequent years (just as the position of the horse in 
halfway through the race is related to its speed in the 
early part of the race and hence speed for the final part 
of the race).45 46 Regression to the mean, due to inclusion 
of people with randomly high (or low) measured lung 
function in the primary studies, may also have contrib-
uted to heterogeneity of the results.47 A simple way that 
primary studies may assess for a horse racing effect, while 
allowing for regression to the mean, is by constructing 
Bland–Altman plots of change versus mean FEV1 level
48 
(or substituting PEFR for mean FEV1 as these are highly 
correlated).49
Comparison with previous research
To date, there have been no systematic reviews or 
meta-analyses examining the rate of lung function 
decline with age to assess the potential impact of the fixed 
threshold on COPD misdiagnosis. Cross-sectional studies 
have compared people diagnosed with COPD using a 
fixed threshold and the LLN definition, reporting that 
the GOLD criteria leads to misdiagnosis of COPD.5–8 50 A 
prospective cohort study found that the fixed threshold 
of the GOLD criteria overdiagnosed a large proportion 
of elderly people over the age of 70 years, and the LLN 
criteria tended to underdiagnose COPD, when compared 
with the reference standard which consisted of an expert 
panel who used all available diagnostic information 
including spirometry.18
Meaning of the study: possible explanations and implications 
for clinicians and policy-makers
This review has found that lung function declines with 
age in all studied populations. The rate of decline 
appears to accelerate with age, and age-specific estimates 
of FEV1, FVC and FEV1/FVC ratio may be more appro-
priate for the diagnosis of COPD than the fixed threshold 
Figure 6 Graphical representation of the risk of bias in prospective cohort studies estimating the rate of lung function decline 
with age.
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currently used across all ages. Currently, prediction 
equations for calculating mean lung function values as 
well as the lower limit of normal (LLN) for all ages are 
based on data from cross-sectional studies; however; it is 
argued that this is problematic as they do not factor in 
the important dimension of time.51 52Spirometers used 
in practice commonly derive their reference values from 
the National Health and Nutrition Examination Survey 
(NHANES), a cross-sectional study which was conducted 
in the USA between 1988 and 1994. Though the predicted 
values do reflect a decline in FEV1 and FEV1/FVC with 
age, these decline rates may not be as reliable as the esti-
mates from longitudinal studies included in our review. 
According to the NHANES III, the median rate of FEV1 
decline for a Caucasian male with an average height 
of 1.75 m aged between 30 and 80 is 32 mL/year and a 
female with an average height of 1.6 m has an FEV1 that 
declines a median of 25 mL/year. Both of these estimates 
are lower than the median FEV1 decline of the studies 
in our review, which was 43.5 mL/year and 30.5 mL/
year for men and women, respectively. Therefore, the 
predicted age-specific lung function used in spirometers 
may often mislabel people as having abnormal lung func-
tion when they are actually within normal limits.53 More 
reliable age-specific estimates and prediction equations 
are required.
Clinicians need to consider whether ‘abnormal’ spirom-
etry results may in fact represent normal ageing. This is 
especially true for making a formal diagnosis of COPD. 
If a patient is symptomatic and has airflow obstruction as 
defined by GOLD criteria, it may be necessary to consider 
alternative diagnoses such as a dyspnoea of cardiac 
origin. One proposal for identifying individuals who are 
experiencing greater loss of lung function than expected 
is to develop ‘decline charts’ that predict FEV1 or FEV1/
FVC loss for different ages. This can allow clinicians to 
monitor lung function over time and assess whether indi-
viduals are tracking along expected decline curves. These 
would also need to account for noise in measurement.
Future research should focus on conducting long-term 
longitudinal studies in less-studied populations, with 
emphasis on older adults. These studies should examine 
the rates of decline in people who eventually become 
symptomatic or develop disease. This information can 
guide clinicians to predict what rate of lung function 
decline may be a prognostic indicator of COPD onset and 
progression. Further well-designed prospective studies 
that investigate changes in FEV1/FVC may allow for the 
development of algorithms that predict individuals’ 
expected lung function over time according to their sex, 
smoking history, age, BMI and ethnicity. The observed 
change in lung function parameters might then be 
compared with the expected change to help the clinician 
determine whether this is extreme enough to warrant 
diagnosis of disease.
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